Evelo Biosciences, Inc. (EVLO)
Sector: Biotechnology
Industry: Biotechnology
Evelo Biosciences, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 21, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 1,284 |
| Oct 6, 2026 | 0.0002 | 0.0002 | 0.0002 | 0.0002 | 370 |
| Oct 5, 2026 | 0.0002 | 0.0002 | 0.0002 | 0.0002 | 166,718 |
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases.
Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
30d Avg
1.28K
60d Avg
42.20K
90d Avg
28.20K